ValuEngine downgraded shares of Audentes Therapeutics (NASDAQ:BOLD) from a strong-buy rating to a buy rating in a research note published on Saturday, ValuEngine reports.

Other equities research analysts also recently issued reports about the stock. Svb Leerink raised their target price on shares of Audentes Therapeutics from $37.00 to $48.00 and gave the company an outperform rating in a research note on Wednesday, April 17th. Piper Jaffray Companies raised their target price on shares of Audentes Therapeutics from $45.00 to $55.00 and gave the company a positive rating in a research note on Monday, April 8th. Wedbush raised their target price on shares of Audentes Therapeutics from $52.00 to $57.00 and gave the company an outperform rating in a research note on Tuesday, April 9th. BidaskClub upgraded shares of Audentes Therapeutics from a buy rating to a strong-buy rating in a research note on Friday, May 17th. Finally, HC Wainwright set a $48.00 target price on shares of Audentes Therapeutics and gave the company a buy rating in a research note on Wednesday, May 8th. Two analysts have rated the stock with a sell rating, three have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $39.92.

Shares of BOLD stock opened at $39.94 on Friday. The company has a market cap of $1.72 billion, a P/E ratio of -11.75 and a beta of 1.85. Audentes Therapeutics has a 52-week low of $17.95 and a 52-week high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.23). During the same quarter in the prior year, the firm earned ($0.74) EPS. As a group, equities analysts predict that Audentes Therapeutics will post -4.43 EPS for the current year.

In other news, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction on Monday, February 25th. The shares were sold at an average price of $30.06, for a total transaction of $300,600.00. Following the completion of the sale, the vice president now directly owns 28,236 shares in the company, valued at $848,774.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew R. Patterson sold 21,000 shares of Audentes Therapeutics stock in a transaction on Monday, February 25th. The stock was sold at an average price of $30.00, for a total transaction of $630,000.00. Following the sale, the chief executive officer now owns 135,700 shares of the company’s stock, valued at $4,071,000. The disclosure for this sale can be found here. Insiders have sold 61,000 shares of company stock valued at $2,020,400 over the last quarter. Insiders own 5.30% of the company’s stock.

Several large investors have recently bought and sold shares of BOLD. Great Point Partners LLC acquired a new stake in shares of Audentes Therapeutics during the fourth quarter worth $35,346,000. Partner Fund Management L.P. lifted its stake in shares of Audentes Therapeutics by 94.4% during the fourth quarter. Partner Fund Management L.P. now owns 3,021,259 shares of the biotechnology company’s stock worth $64,413,000 after buying an additional 1,467,120 shares during the period. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of Audentes Therapeutics by 913.5% during the first quarter. Gilder Gagnon Howe & Co. LLC now owns 1,619,831 shares of the biotechnology company’s stock worth $63,206,000 after buying an additional 1,459,999 shares during the period. BB Biotech AG acquired a new stake in shares of Audentes Therapeutics during the fourth quarter worth $16,404,000. Finally, Millennium Management LLC acquired a new stake in shares of Audentes Therapeutics during the fourth quarter worth $12,600,000. Institutional investors and hedge funds own 97.81% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: Closed-End Mutual Funds

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.